Type: Bradykinin B2 Receptor Antagonist
Therapies & Conditions: Indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults.
Administration: 30 mg injected subcutaneously in the abdominal area; do not administer more than 3 injections in 24 hours. If response is inadequate or symptoms recur, additional injections of 30 mg may be administered at intervals of at least 6 hours.
Method: Intravenous (IV) infusion only
Side Effects: The most commonly reported adverse reactions were injection site reactions; other common reactions include pyrexia, transaminase increase, dizziness, and rash.
For more detailed information on Firazyr, please visit FDA.gov
Frequently Asked Questions
- What is infusion therapy?
Infusion therapy involves the administration of medication through a needle or catheter. It is usually prescribed when a patient’s condition cannot be treated with oral medication. Read more about infusion therapy treatments.
- Is home infusion therapy safe?
Home and alternate site infusion therapy is a proven, safe and effective alternative to hospital inpatient care.[*]Bhole, M. V., Burton, J., & Chapel, H. M. (2008). Self-infusion programmes for immunoglobulin replacement at home: Feasibility, safety and efficacy. Immunology and Allergy Clinics of North America,28(4), 821-832. [*]Souayah, N., Hasan, A., Khan, H., et al. (2011). The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.Journal of Clinical Neuromuscular Disease, 12(suppl 4), S1-10. For most people, receiving treatment at home or in an alternate treatment setting, like an infusion suite, is preferable to hospital inpatient care. It can provide comfort and convenience for patients and offers less interruption to their daily activities. It can also be a cost-effective alternative to expensive hospital stays.[*]Home infusion therapy: Differences between Medicare and private insurers’ coverage. (2010, June). United States Government Accountability Office Report to Congressional Requesters. Accessed July 23, 2012: http://www.gao.gov/assets/310/305261.pdf. [*]Einodshofer, M. (2012). A plan for medical specialty medications – increase member access, affordability and outcomes while decreasing plan costs. Presented at: 2012 Pharmacy Benefit Management Institute Annual Drug Benefit Conference; 2012 Feb. 22-24; Scottsdale, Ariz.
- Am I a candidate for home or alternate site infusion therapy?
The decision to receive infusion therapy in the home or at an alternate site is made between you and your doctor or healthcare provider. Several factors are considered before a patient can receive infusion therapy in the home, including the patient’s and/or caregiver’s desire and willingness to comply with therapy and the presence of a safe and appropriate home environment.